HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
ciprostene
structure given in first source
Also Known As:
9beta-methyl-6alpha-carbaprostaglandin I2; 9beta-methylcarbacyclin; Pentanoic acid, 5-(hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1H)-pentalenylidene)-, (3aS-(2Z,3aalpha,5beta,6alpha(1E,3R*),6aalpha))-
Networked:
7
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins I: 108
Epoprostenol: 4670
ciprostene: 7
Biological Factors: 2472
Inflammation Mediators: 1113
Autacoids: 276
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins I: 108
Epoprostenol: 4670
ciprostene: 7
Related Diseases
1.
Pain (Aches)
01/01/1991 - "
Both ciprostene and placebo reduced the severity of a patient's rest pain.
"
2.
Ulcer
01/01/1991 - "
Among those who completed the trials an insignificantly higher percentage of patients receiving ciprostene had all ulcers heal completely.
"
01/01/1991 - "
Good tolerance and safety of ciprostene was documented in this patient population, and the therapeutic benefit was limited to partial reduction of ulcer size.
"
01/01/1991 - "
The reduction of ulcer size by at least 50% was higher in the ciprostene-treated group at month 4 (P = .005).
"
01/01/1991 - "
The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers.
"
01/01/1991 - "
This randomized, double-blind study investigated the effect of ciprostene, a stable epoprostenol (prostacyclin) analog in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers.
"
3.
Peripheral Vascular Diseases (Peripheral Vascular Disease)
02/01/1993 - "
Ten patients with peripheral vascular disease and claudication received ciprostene (titrated to 120 ng/kg/min) infused over 8 hours 1 day per week for 4 consecutive weeks.
"
10/01/1988 - "
Ciprostene in patients with peripheral vascular disease (PVD).
"
01/01/1991 - "
The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers.
"
01/01/1991 - "
This randomized, double-blind study investigated the effect of ciprostene, a stable epoprostenol (prostacyclin) analog in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers.
"
4.
Coronary Stenosis (Coronary Artery Stenosis)
01/01/1992 - "
In contrast, coronary artery stenoses in patients receiving ciprostene (n = 12) measured 83 +/- 3% before PTCA, 31 +/- 4% after PTCA and 55 +/- 9% at 6 month, being still significantly different from pre-PTCA value (P less than 0.05).
"
5.
Necrosis
06/01/1992 - "
Therefore, the results demonstrated that administration of ciprostene and indomethacin either alone or together partially reversed the pathophysiological mechanisms that cause necrosis of random skin flap distal end.
"
06/01/1992 - "
Ciprostene and indomethacin partially reverse the mechanisms of distal end necrosis in the rat random skin flap.
"
Related Drugs and Biologics
1.
Epoprostenol (Prostacyclin)
2.
Calcium
3.
Cyclooxygenase Inhibitors
4.
Verapamil (Calan)
5.
Thromboxane A2 (A2, Thromboxane)
6.
Sodium
7.
Phosphotransferases (Kinase)
8.
Pentobarbital (Nembutal)
9.
Nifedipine (Adalat)
10.
Meclofenamic Acid (Meclofenamate)